Loading...
Biocept, Inc.
BIOC•NASDAQ
Healthcare
Medical - Diagnostics & Research
$0.43
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $5.59M in Q3 2022 to $589000.00 in Q2 2023. Gross profit continued to perform well, with margins at -333% in the latest quarter. Operating income reached -$6.11M in Q2 2023, holding a steady -1038% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$5.65M. Net income rose to -$3.63M, keeping EPS at -$3.50. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan